SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$4M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SHPH vs CELC
Revenue, margins, valuation, and 5-year total return — side by side.
CELC
Celcuity Inc.
Biotechnology
Market Cap$5.66B
5Y Perf.+1298.0%
SHPH vs CELC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SHPH | CELC |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $4M | $5.66B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-163M |
| Total Debt | $1M | $98M |
| Cash & Equiv. | $2M | $23M |
SHPH vs CELC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SHPH
CELC
| Stock | Aug 22 | May 26 | Return |
|---|---|---|---|
| Shuttle Pharmaceuti… (SHPH) | 100 | 0.0 | -100.0% |
| Celcuity Inc. (CELC) | 100 | 1398.0 | +1298.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHPH vs CELC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CELC leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Shuttle Pharmaceuticals Holdings, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The Income Pick
SHPH is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.24
- Lower volatility, beta 1.24, current ratio 1.44x
- Beta 1.24, current ratio 1.44x
Best for: income & stability and sleep-well-at-night
CELC
Celcuity Inc.
The Growth Play
CELC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth -5.2%
- 8.1% 10Y total return vs SHPH's -100.0%
- 0.6% margin vs SHPH's -52.7%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SHPH | -16.6% revenue growth vs CELC's -73.2% |
| Quality / Margins | CELC | 0.6% margin vs SHPH's -52.7% |
| Stability / Safety | SHPH | Beta 1.24 vs CELC's 1.71 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CELC | +11.8% vs SHPH's -89.1% |
| Efficiency (ROA) | CELC | -58.0% ROA vs SHPH's -253.9%, ROIC -50.3% vs -456.4% |
SHPH vs CELC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCELCLAGGINGSHPH
SHPHShuttle Pharmaceutica…
0leads
CELCCelcuity Inc.
3leads
6 Total Categories
CATEGORYLEADERvs SHPHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CELC1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CELC6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CELC6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CELC leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SHPH and CELC operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | SHPHShuttle Pharmaceu… | CELCCelcuity Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$11M | -$159M |
| Net IncomeAfter-tax profit | -$11M | -$163M |
| Free Cash FlowCash after capex | -$11M | -$145M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -183.8% | -31.4% |
CELC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SHPH and CELC each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SHPHShuttle Pharmaceu… | CELCCelcuity Inc. |
|---|---|---|
| Market CapShares × price | $4M | $5.7B |
| Enterprise ValueMkt cap + debt − cash | $3M | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -46.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 10.28x | 44.60x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SHPH and CELC each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CELC leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CELC delivers a -179.0% return on equity — every $100 of shareholder capital generates $-179 in annual profit, vs $-5 for SHPH. CELC carries lower financial leverage with a 0.85x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHPH's 1.65x. On the Piotroski fundamental quality scale (0–9), SHPH scores 2/9 vs CELC's 1/9, reflecting mixed financial health.
| Metric | SHPHShuttle Pharmaceu… | CELCCelcuity Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -4.8% | -179.0% |
| ROA (TTM)Return on assets | -2.5% | -58.0% |
| ROICReturn on invested capital | -4.6% | -50.3% |
| ROCEReturn on capital employed | -2.6% | -58.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 1.65x | 0.85x |
| Net DebtTotal debt minus cash | -$746,672 | $75M |
| Cash & Equiv.Liquid assets | $2M | $23M |
| Total DebtShort + long-term debt | $1M | $98M |
| Interest CoverageEBIT ÷ Interest expense | -50.60x | -5.02x |
CELC leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CELC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CELC five years ago would be worth $48,161 today (with dividends reinvested), compared to $1 for SHPH. Over the past 12 months, CELC leads with a +1184.0% total return vs SHPH's -89.1%. The 3-year compound annual growth rate (CAGR) favors CELC at 140.6% vs SHPH's -86.0% — a key indicator of consistent wealth creation.
| Metric | SHPHShuttle Pharmaceu… | CELCCelcuity Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -61.0% | +30.0% |
| 1-Year ReturnPast 12 months | -89.1% | +1184.0% |
| 3-Year ReturnCumulative with dividends | -99.7% | +1292.0% |
| 5-Year ReturnCumulative with dividends | -100.0% | +381.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | +814.7% |
| CAGR (3Y)Annualised 3-year return | -86.0% | +140.6% |
CELC leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SHPH and CELC each lead in 1 of 2 comparable metrics.
Risk & Volatility
SHPH is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than CELC's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CELC currently trades 86.6% from its 52-week high vs SHPH's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SHPHShuttle Pharmaceu… | CELCCelcuity Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.71x |
| 52-Week HighHighest price in past year | $11.25 | $151.02 |
| 52-Week LowLowest price in past year | $0.50 | $9.51 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +86.6% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 840K | 800K |
Evenly matched — SHPH and CELC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SHPHShuttle Pharmaceu… | CELCCelcuity Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $124.75 |
| # AnalystsCovering analysts | — | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CELC leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallCelcuity Inc. (CELC)Leads 3 of 6 categories
Loading custom metrics...
SHPH vs CELC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SHPH or CELC a better buy right now?
Analysts rate Celcuity Inc.
(CELC) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SHPH or CELC?
Over the past 5 years, Celcuity Inc.
(CELC) delivered a total return of +381. 6%, compared to -100. 0% for Shuttle Pharmaceuticals Holdings, Inc. (SHPH). Over 10 years, the gap is even starker: CELC returned +814. 7% versus SHPH's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SHPH or CELC?
By beta (market sensitivity over 5 years), Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the lower-risk stock at 1. 24β versus Celcuity Inc. 's 1. 71β — meaning CELC is approximately 38% more volatile than SHPH relative to the S&P 500. On balance sheet safety, Celcuity Inc. (CELC) carries a lower debt/equity ratio of 85% versus 165% for Shuttle Pharmaceuticals Holdings, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SHPH or CELC?
On earnings-per-share growth, the picture is similar: Celcuity Inc.
grew EPS -5. 2% year-over-year, compared to -2159. 3% for Shuttle Pharmaceuticals Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SHPH or CELC?
Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Celcuity Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHPH leads at 0. 0% versus 0. 0% for CELC. At the gross margin level — before operating expenses — SHPH leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SHPH or CELC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SHPH or CELC better for a retirement portfolio?
For long-horizon retirement investors, Celcuity Inc.
(CELC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+814. 7% 10Y return). Both have compounded well over 10 years (CELC: +814. 7%, SHPH: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SHPH and CELC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.